Abstract:Background The mammalian target of rapamycin (mTOR) pathway plays a significant role in osteogenic differentiation and bone maintenance. As the only known endogenous inhibitor of mTOR function, DEP domain containing mTOR interacting protein (DEPTOR) is potentially involved in stem cell differentiation, although the pathophysiological significance and its molecular mechanisms remain unclear. The present study aimed to elucidate the effects of DEPTOR on the progress of osteoporosis and investigate the underlying molecular mechanisms of osteogenic regulation. Methods An ovariectomy mouse model with decreased bone formation and osteogenic induction with bone marrow mesenchymal stem cells (BMSCs) were used to investigate the relationship between DEPTOR and osteogenic events. A loss-of-function investigation was then performed to explore the role of DEPTOR in the osteogenic differentiation of BMSCs both in vitro and in vivo. Finally, long noncoding RNA (lncRNA) and mRNA sequences were investigated to reveal the underlying mechanisms of DEPTOR in osteogenic regulation. RNA interference, western blotting, and chromatin immunoprecipitation assays were performed for further mechanistic determination. Results The results indicated that DEPTOR contributes to the progress of osteoporosis, and higher expression of Deptor was observed in osteoporotic bones. The expression of DEPTOR was reduced during the osteogenic differentiation of BMSCs, and knockdown of DEPTOR promoted BMSC osteogenesis in vitro and in vivo. lncRNA and mRNA sequences indicated that knockdown of DEPTOR upregulated the expression of maternally expressed 3 (nonprotein coding) ( MEG3 ), which subsequently activated bone morphogenetic protein 4 (BMP4) signaling. Furthermore, DEPTOR could bind to a specific region (− 1000 bp ~ 0) of the MEG3 promoter to regulate its transcription, and inhibition of MEG3 reduced BMP4 activation triggered by DEPTOR knockdown. Conclusions Taken together, our study revealed a novel function of DEPTOR in osteogenic differentiation by inhibiting MEG3-mediated activation of BMP4 signaling, which suggested that DEPTOR could be a therapeutic target for bone loss diseases and skeletal tissue regeneration.

Abstract 4160: DEPTOR, an mTOR inhibitor, is a novel substrate of SCFαTrCP E3 ubiquitin ligase upon S6K1/RSK1 phosphorylation and regulates survival and autophagy

DEPTOR, an mTOR inhibitor, is a physiological substrate of SCF(βTrCP) E3 ubiquitin ligase and regulates survival and autophagy.

DEPTOR is a Direct P53 Target That Suppresses Cell Growth and Chemosensitivity

DEPTOR Stabilizes ErbB2 to Promote the Proliferation and Survival of ErbB2-positive Breast Cancer Cells.

Targeting the Mtor-Deptor Pathway by CRL E3 Ubiquitin Ligases: Therapeutic Application

DEPTOR Inhibits Lung Tumorigenesis by Inactivating the EGFR-mTOR Signals.

Tyrosine phosphorylation of DEPTOR functions as a molecular switch to activate mTOR signaling

DEPTOR is an in Vivo Tumor Suppressor That Inhibits Prostate Tumorigenesis Via the Inactivation of Mtorc1/2 Signals

Deptor Has Growth Suppression Activity Against Pancreatic Cancer Cells

Regulatory Function of Phosphorylation and Ubiquitination on The TORC1 Signaling Pathway

The cross talk of two family members of β-TrCP in the regulation of cell autophagy and growth

Elucidating the role of DEPTOR in Alzheimer’s disease

Loop modelling provides insights into regulation of mTORC1 activity via DEPTOR dimerisation

The Mtor–s6k Pathway Links Growth Signalling to DNA Damage Response by Targeting RNF168

Nuclear ErbB2 Represses DEPTOR Transcription to Inhibit Autophagy in Breast Cancer Cells

DEPTOR regulates osteogenic differentiation via inhibiting MEG3-mediated activation of BMP4 signaling and is involved in osteoporosis

DEPTOR induces a partial epithelial-to-mesenchymal transition and metastasis via autocrine TGFβ1 signaling and is associated with poor prognosis in hepatocellular carcinoma

DEPTOR Prevents Osteoarthritis Development Via Interplay With TRC8 to Reduce Endoplasmic Reticulum Stress in Chondrocytes

Targeting the mTOR pathway using deforolimus in cancer therapy

The N-terminal Phosphodegron Targets TAZ/WWTR1 Protein for SCFβ-TrCP-dependent Degradation in Response to Phosphatidylinositol 3-Kinase Inhibition

RagC phosphorylation autoregulates mTOR complex 1